Tipranks Press Release.
Gossamer Bio’s modeled fair value has shifted from US$1.66 to US$82.48, reflecting the 1 for 80 reverse stock split and refreshed valuation work. Street research links these reset price targets to a split view on risk and reward for seralutinib as it moves toward a planned PAH NDA submission, with analysts weighing FDA feedback, trial data and single asset concentration. As you read on, you will see how to track these changing targets and what might matter most for following the evolving...
Detailed price information for Gossamer Bio Inc (GOSS-Q) from The Globe and Mail including charting and trades.
Gossamer Bio (GOSS) said late Wednesday it has submitted a new drug application to the US Food and D
SAN DIEGO, September 23, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatme
Detailed price information for Gossamer Bio Inc (GOSS-Q) from The Globe and Mail including charting and trades.
SAN DIEGO, September 16, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that Greg Ciongoli has been appointed to the Company's Board of Directors, effective September 16, 2026. Mr. Ciongoli will also serve as a member of the Audit Committee.
SAN DIEGO, September 04, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026.
Gossamer Bio, Inc. (NASDAQ:GOSS) announced a structured private placement on August 21 that could generate up to approximately $250 million in gross proceeds. However, Gossamer Bio, Inc. (NASDAQ:GOSS) divided the financing into three stages, leaving most of the headline amount dependent on regulatory milestones. At the initial closing, Gossamer Bio, Inc. (NASDAQ:GOSS) expects approximately $25 […]
The proceeds will help advance seralutinib's clinical development and potential commercialisation.
Gossamer Bio has structured the financing around key seralutinib regulatory milestones, with $150 million committed and another $100 million potentially available if the pulmonary arterial hypertension drug receives FDA approval. Key Investor TakeawaysGossamer Bio (NASDAQ:GOSS) has secured up to $250 million through a structured private placement tied to seralutinib’s regulatory progress.
Gossamer Bio (GOSS) shares were up 10% in Friday's premarket trading after the company said it has a
SAN DIEGO, August 21, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional investors for a private placement financing e
This is the newest page. Registered accounts read further back.